A Trial of Ipatasertib in Combination With Atezolizumab

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

August 13, 2018

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Solid TumorGlioblastoma MultiformeProstate Cancer Metastatic
Interventions
DRUG

ipatasertib

Ipatasertib will be supplied as film-coated tablets in two strengths (100 and 200 mg) differentiated by size, shape, and weight of tablets. Ipatasertib tablets are packaged in high-density polyethylene bottles with desiccant.

DRUG

Atezolizumab

Atezolizumab will be supplied as a single-use 20 mL USP/Ph. Eur Type 1 glass vial as a colourless-to-slightly-yellow, sterile, preservative-free clear liquid solution intended for intravenous (IV) administration.

Trial Locations (1)

SM2 5PT

Royal Marsden Hospital NHS Foundation Trust, Sutton

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

Institute of Cancer Research, United Kingdom

OTHER

NCT03673787 - A Trial of Ipatasertib in Combination With Atezolizumab | Biotech Hunter | Biotech Hunter